TW201408650A - 尿素化合物及其作爲酵素抑制劑之用途 - Google Patents
尿素化合物及其作爲酵素抑制劑之用途 Download PDFInfo
- Publication number
- TW201408650A TW201408650A TW102126473A TW102126473A TW201408650A TW 201408650 A TW201408650 A TW 201408650A TW 102126473 A TW102126473 A TW 102126473A TW 102126473 A TW102126473 A TW 102126473A TW 201408650 A TW201408650 A TW 201408650A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- disease
- faah
- methylcyclopentylamine
- salt
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 230000001154 acute effect Effects 0.000 claims abstract description 8
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 7
- 208000006011 Stroke Diseases 0.000 claims abstract description 7
- 230000036506 anxiety Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 6
- 208000012661 Dyskinesia Diseases 0.000 claims abstract description 5
- 206010028813 Nausea Diseases 0.000 claims abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 206010047700 Vomiting Diseases 0.000 claims abstract description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 208000006673 asthma Diseases 0.000 claims abstract description 5
- 208000035475 disorder Diseases 0.000 claims abstract description 5
- 206010015037 epilepsy Diseases 0.000 claims abstract description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 5
- 230000008693 nausea Effects 0.000 claims abstract description 5
- 230000036407 pain Effects 0.000 claims abstract description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 4
- 206010006895 Cachexia Diseases 0.000 claims abstract description 4
- 208000014094 Dystonic disease Diseases 0.000 claims abstract description 4
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 4
- 206010020772 Hypertension Diseases 0.000 claims abstract description 4
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims abstract description 4
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 4
- 206010038923 Retinopathy Diseases 0.000 claims abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 4
- 208000022531 anorexia Diseases 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims abstract description 4
- 230000005796 circulatory shock Effects 0.000 claims abstract description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 4
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 4
- 206010013663 drug dependence Diseases 0.000 claims abstract description 4
- 208000010118 dystonia Diseases 0.000 claims abstract description 4
- 208000006454 hepatitis Diseases 0.000 claims abstract description 4
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 4
- 206010022437 insomnia Diseases 0.000 claims abstract description 4
- 208000019423 liver disease Diseases 0.000 claims abstract description 4
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 3
- 208000030090 Acute Disease Diseases 0.000 claims abstract description 3
- 206010061218 Inflammation Diseases 0.000 claims abstract description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 3
- 206010029350 Neurotoxicity Diseases 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims abstract description 3
- 235000021229 appetite regulation Nutrition 0.000 claims abstract description 3
- 229960003920 cocaine Drugs 0.000 claims abstract description 3
- 230000004054 inflammatory process Effects 0.000 claims abstract description 3
- 230000007135 neurotoxicity Effects 0.000 claims abstract description 3
- 231100000228 neurotoxicity Toxicity 0.000 claims abstract description 3
- 229960002715 nicotine Drugs 0.000 claims abstract description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 229940127240 opiate Drugs 0.000 claims abstract description 3
- 239000003368 psychostimulant agent Substances 0.000 claims abstract description 3
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 32
- 229930003827 cannabinoid Natural products 0.000 claims description 19
- 239000003557 cannabinoid Substances 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 12
- KKTBUCVHSCATGB-UHFFFAOYSA-N n-methylcyclopentanamine Chemical compound CNC1CCCC1 KKTBUCVHSCATGB-UHFFFAOYSA-N 0.000 claims description 12
- 229940065144 cannabinoids Drugs 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 8
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 239000002621 endocannabinoid Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims description 4
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000006371 metabolic abnormality Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000006268 reductive amination reaction Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- WWASAZBMXLYJCT-KTKRTIGZSA-N (z)-1-aminoicos-11-en-2-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCC(O)CN WWASAZBMXLYJCT-KTKRTIGZSA-N 0.000 claims description 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 208000020431 spinal cord injury Diseases 0.000 abstract description 2
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 239000000725 suspension Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- -1 carbamate compound Chemical class 0.000 description 20
- 229940125904 compound 1 Drugs 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000002002 slurry Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000002619 bicyclic group Chemical group 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GZHPNIQBPGUSSX-UHFFFAOYSA-N 2-bromo-1-(3-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)CBr)=C1 GZHPNIQBPGUSSX-UHFFFAOYSA-N 0.000 description 4
- SSTAZAXODYHDRC-UHFFFAOYSA-N 4-(3-aminophenyl)-n-cyclopentyl-n-methylimidazole-1-carboxamide Chemical compound C1=NC(C=2C=C(N)C=CC=2)=CN1C(=O)N(C)C1CCCC1 SSTAZAXODYHDRC-UHFFFAOYSA-N 0.000 description 4
- SXKWDPMBWTZYCA-UHFFFAOYSA-N 4-[3-(carbamoylamino)phenyl]-n-cyclopentyl-n-methylimidazole-1-carboxamide Chemical compound C1=NC(C=2C=C(NC(N)=O)C=CC=2)=CN1C(=O)N(C)C1CCCC1 SXKWDPMBWTZYCA-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- 229940011051 isopropyl acetate Drugs 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 4
- DTMTYKUCZFYAEU-UHFFFAOYSA-N n-methylcyclopentanamine;hydrochloride Chemical compound Cl.CNC1CCCC1 DTMTYKUCZFYAEU-UHFFFAOYSA-N 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101150051438 CYP gene Proteins 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 201000002661 Spondylitis Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- OIPQMWUMUMFFKB-UHFFFAOYSA-N n-cyclopentyl-n-methyl-4-(3-nitrophenyl)imidazole-1-carboxamide Chemical compound C1=NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CN1C(=O)N(C)C1CCCC1 OIPQMWUMUMFFKB-UHFFFAOYSA-N 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LJKYKFRQAQCNIN-DOFZRALJSA-N 2-[[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenyl]amino]ethanol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCNCCO LJKYKFRQAQCNIN-DOFZRALJSA-N 0.000 description 2
- ZNOVTXRBGFNYRX-UHFFFAOYSA-N 2-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- AMSITKGZVUXDQM-UHFFFAOYSA-N 5-(3-nitrophenyl)-1h-imidazole Chemical compound [O-][N+](=O)C1=CC=CC(C=2NC=NC=2)=C1 AMSITKGZVUXDQM-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- QLYLXTXSBAIXEN-UHFFFAOYSA-N CNC1CCCC1.NN=CN=N.Cl Chemical compound CNC1CCCC1.NN=CN=N.Cl QLYLXTXSBAIXEN-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 102000011040 TRPV Cation Channels Human genes 0.000 description 2
- 108010062740 TRPV Cation Channels Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 208000037156 Choroid plexus tumor Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- SFIHQZFZMWZOJV-UHFFFAOYSA-N Linolsaeure-amid Natural products CCCCCC=CCC=CCCCCCCCC(N)=O SFIHQZFZMWZOJV-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 208000013355 benign neoplasm of brain Diseases 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CBIKNPNOQWAFBJ-UHFFFAOYSA-N ethyl n-cyclopentylcarbamate Chemical compound CCOC(=O)NC1CCCC1 CBIKNPNOQWAFBJ-UHFFFAOYSA-N 0.000 description 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- SFIHQZFZMWZOJV-HZJYTTRNSA-N linoleamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(N)=O SFIHQZFZMWZOJV-HZJYTTRNSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YQNQTEBHHUSESQ-UHFFFAOYSA-N lithium aluminate Chemical compound [Li+].[O-][Al]=O YQNQTEBHHUSESQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FBSDLEDJKXQUHB-UHFFFAOYSA-L magnesium tridecanoate Chemical compound [Mg++].CCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCC([O-])=O FBSDLEDJKXQUHB-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
- C07C209/26—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
一種具有下列結構之化合物:□或其藥學上可接受之鹽或衍生物。此化合物可用於治療或預防選自下列之異常:食欲調節、肥胖、代謝異常、惡病質、厭食、疼痛、發炎、神經毒性、神經外傷、中風、多發性硬化症、脊椎損傷、巴金森氏症、左多巴誘發異動症、享丁頓舞蹈症、妥瑞症、遲發性運動不能、肌張力不全、肌萎縮性側索硬化症、阿茲罕默氏症、癲癇、精神分裂症、焦慮、憂慮、失眠、噁心、嘔吐、酒精障礙、諸如鴉片劑、尼古汀、古柯鹼、酒精,及精神興奮劑之藥物成癮、高血壓、循環休克、心肌再灌注損傷、動脈粥狀硬化、氣喘、青光眼、視網膜病變、癌症、發炎性腸病、諸如肝炎及肝硬化之急性及慢性肝病、關節炎,及骨質疏鬆症。
Description
本發明係有關於化合物及其等之用途,且特別係化合物及其等於治療或預防具有與基質有關係之病況的治療用途,諸如,神經傳遞物大麻素,其係藉由脂肪酸醯胺水解酶(FAAH)酵素分解。
FAAH酵素分解脂肪酸醯胺,諸如,大麻素(N-花生四烯醯基乙醇胺)、N-油醯基乙醇胺、N-棕櫚醯乙醇胺,及油醯胺。大麻素,亦稱為N-花生四烯醯基乙醇胺或AEA,係於動物及人類器官,特別是於腦部,發現之一內源性大麻素神經傳遞物。亦已發現大麻素與類香草素受體結合。大麻素係藉由脂肪酸醯胺水解酶(FAAH)酵素降解成乙醇胺及花生四烯酸。因此,FAAH之抑制劑導致升高之大麻素量。
大麻素內源性大麻素系統之一神經傳遞物,且刺激大麻素受體。諸如CB1及CB2之大麻素受體係G蛋白偶合受體。CB1主要係於中樞神經系統發現,而CB2主要係於週
邊組織發生。內源性大麻素系統牽涉到漸增數量之生理功能,於中樞及週邊神經系統及於週邊器官二者。內源性大麻素系統活性調節已顯示對於廣泛範圍之不同疾病及病理病況具有可能治療效果。因此,內源性大麻素系統,且特別是FAAH酵素,已變成用於發展許多疾病之可能治療的一治療目標。內源性大麻素系統已牽涉到許多食欲調節、肥胖、代謝異常、惡病質、厭食、疼痛、發炎、神經毒性、神經外傷、中風、多發性硬化症、脊椎損傷、巴金森氏症、左多巴誘發異動症、享丁頓舞蹈症、妥瑞症、遲發性運動不能、肌張力不全、肌萎縮性側索硬化症、阿茲罕默氏症、癲癇、精神分裂症、焦慮、憂慮、失眠、噁心、嘔吐、酒精障礙、諸如鴉片劑、尼古汀、古柯鹼、酒精,及精神興奮劑之藥物成癮、高血壓、循環休克、心肌再灌注損傷、動脈粥狀硬化、氣喘、青光眼、視網膜病變、癌症、發炎性腸病、諸如肝炎及肝硬化之急性及慢性肝病、關節炎,及骨質疏鬆症。內源性大麻素及其相關之病況係於Pacher等人之(2006)Pharmacol.Rev.58:389-462中詳細探討。
為調節諸如大麻素之內源性FAAH基質的量,其因而調節內源性大麻素系統,已發展出FAAH酵素之抑制劑。此能使與內源性大麻素系統有關之病況及疾病至少部份被治療及預防。
因為FAAH之基質與例如類香草素受體之其它受體結合,及/或,涉及其它信號通路,FAAH之抑制劑亦能使與例如類香草素系統之其它通路或系統有關之病況或疾
病至少部份被治療或預防。
WO 2010/074588揭示係FAAH抑制劑之化合物。Käsnänen等人(Heikki Käsnänen、Mikko J.Myllymäki、Anna Minkkilä、Antti O.Kataja、Susanna M.Saario、Tapio Nevalainen、Ari M.P.Koskinen,及Antti Poso.Chem Med Chem 2010,5(2),213-231)揭示係FAAH抑制劑之氨基甲酸酯化合物。特別地,化合物6b係一含有一咪唑結構之FAAH抑制劑。但是,與此論文中描述且不含有一咪唑結構之許多其它氨基甲酸酯化合物相比,此化合物係一弱FAAH抑制劑。
於第一方面,本發明提供一種具有下列結柿表化合物:
或其藥學上可接受之鹽或衍生物。
本發明之化合物已被發現調節酵素脂肪酸醯胺水解酶(FAAH)之活性。再者,已顯示相對較有效,具有相對較高週邊選擇性(即,其於週邊組織係比於中樞神經系統
組織抑制FAAH達更大程度),及係相對上較為代謝安定。特別地,本發明之化合物已顯示與WO 2010/074588中揭露之化合物相比係對一或多種此等性質提供較佳結果。
本發明化合物之‘其藥理學上可接受之鹽包含與無機鹼之鹽、與有機鹼之鹽、與無機酸之鹽、與有機酸之鹽,及與鹼性或酸性胺基酸之鹽。與酸之鹽可特別被用於某些例子。例示之鹽包含氫氯酸鹽、乙酸鹽、三氟乙酸鹽、甲烷磺酸鹽、2-羥基丙烷-1,2,3-三羧酸鹽、(2R,3R)-2,3-二羥基琥珀酸鹽、磷酸鹽、硫酸鹽、苯甲酸鹽、2-羥基-苯甲酸鹽、S-(+)-杏仁酸鹽、S-(-)-蘋果酸鹽、S-(-)焦麩氨酸鹽、丙酮酸鹽、對甲苯磺酸鹽、1-R-(-)-樟腦磺酸鹽、福馬酸鹽,及草酸鹽。本發明之化合物可以溶劑合物(例如,水合物)或非溶劑合物(例如,非水合物)型式使用。當呈溶劑合物型式,另外之溶劑可為醇,諸如,丙-2-醇。
本發明化合物之‘其藥學上可接受之衍生物’係其中此化合物之一或多個基團係藉由與另一分子反應而改質的衍生物。例如,衍生物包含改質NH2基團形成NHR或NR2,其中,R可為C1-18烷基(例如,C1-6烷基)、芳基、雜芳基、C3-8環烷基,或此等之組合。此等衍生物可依據下列流程製造。
例如,衍生物包含4-(3-胺基苯基)-N-環戊基-N-甲基-1H-咪唑-1-羧醯胺之NH2基團與R-N=C=O異氰酸酯(R.G.Arnold,J.A.Nelson,J.J.Verbanc:Recent Advances in Isocyanate Chemistry Chemical Reviews,57(1),47-76,1957及其內之參考資料)反應形成NH-(C=O)-NHR衍生物,或與Cl-(C=O)-Cl及NHR2(見H.Babad,A.G.Zeiler:Chemistry of Phosgene Chemical Reviews,73(1),75-91,1973及其內之參考資料)反應形成NH-(CO)-NR2之產物,其中,R可為C1-18烷基(例如,C1-6烷基),、芳基、雜芳基、C3-8環烷基,或其等之組合。其藥學上可接受之衍生物可以任何適合方式製造,且用於其製造之方法對熟習此項技藝者以有機及藥物化學所知原理為基準係顯見的(例如,適合方法係揭示於Vogel之Textbook of Practical Organic Chemistry,第5版,
Longman,1989)。明顯地,衍生物需能抑制FAAH且需顯示週邊選擇性,即,其等需具有與如上結構相似之性質。測試此等性質之適合方法係熟習此項技藝者所知且於此處描述。
術語'Cx-y烷基'於此處使用時係指一含有x至y個碳原子之線性或分支之飽和烴基團。例如,C1-6烷基係指一含有1至6個碳原子之線性或分支之飽和烴基團。C1-6烷基基團之例子包含甲基、乙基、正丙基、異丙基、正丁基、異丁基、第二丁基、第三丁基、正戊基、異戊基、新戊基,及己基。較佳地,烴基團係線性。
術語‘芳基’於此處使用時係指一其中至少一環係芳香族之C6-12單環狀或二環狀之烴環。此等基團之例子包含苯基、萘基,及四氫萘基。
術語'雜芳基'於此處使用時係指一5-6員之單環狀芳香族或一稠合之8-10員之二環狀芳香族環,此單環狀或二環狀之環含有1至4個選自氧、氮及硫之雜原子。此等單環狀芳香族環之例子包含噻吩基、呋喃基、呋咕基、吡咯基、三唑基、四唑基、咪唑基、唑基、噻唑基、二唑基、異噻唑基、異唑基、噻二唑基、吡喃基、吡唑基、嘧啶基、嗒基、吡基、吡啶基、三基、四基等。此等二環狀芳香族環之例子包含喹啉基、異喹啉基、喹唑啉基、喹啉基、喋啶基、啉基、酞基、萘啶基、吲哚基、異吲哚基、氮雜吲哚、吲基、吲唑基、嘌呤基、吡咯并吡啶基、呋喃并吡啶基、苯并呋喃基、異苯并呋喃
基、苯并噻吩基、苯并咪唑基、苯并唑基、苯并異唑基、苯并噻唑基、苯并異噻唑基、苯并二唑基、苯并噻二唑基,及咪唑并吡啶基。
在二環狀環情況之術語‘二環狀環’及‘稠合’係指經二個原子間之一鍵結結合在一起(例如,萘),經一系列原子結合在一起形成一橋(例如,啶)或以單一原子結合在一起形成一螺旋化合物(例如,1,4-二氧雜-8-氮雜-螺旋[4.5]癸烷及N,3,3-二甲基-1,5-二氧雜螺旋[5.5]十一烷-9-基)之二環。
術語'Cx-y環烷基'於此處使用時係指一具有x至y個碳原子之飽和烴環,其可為單環、二環或三環。例如,C3-8環烷基係指一具有3至8個碳原子之飽和單環、二環或三環之烴環。C3-8環烷基基團之例子包含環丙基、環丁基、環戊基、環己基、環庚基,及環辛基。
用於製備鹽及衍生物之一般方法係熟習此項技藝者所知。鹽及衍生物之藥學上可接受性會因各種不同因素而定,包含調配加工特徵及活體內行為,且熟習此項技藝者會輕易能評估有關於本揭露內容之此等因素。
若本發明之化合物可以交替之互變異構物型式存在(例如,酮/烯醇、醯胺/亞胺酸),本發明係有關於呈隔離之個別互變異構物,及呈所有比率之互變異構物混合物。
依據本發明之第二方面,提供一種藥學組成物,其包含與一或多種藥學上可接受之賦形劑在一起之一依據本發明第一方面之化合物。
本發明之藥學組成物包含任何本發明第一方面之化合物,及任何藥學上可接受之載劑、佐劑,或載體。可用於本發明藥學組成物之藥學上可接受之載劑、佐劑,或載體係傳統上於藥學調配領域使用者,且不受限制地包括糖、糖醇、澱粉、離子交換劑、氧化鋁、硬脂酸鋁、卵磷脂、血清蛋白,諸如,人類血清白蛋白,緩衝物質,諸如,磷酸鹽,甘油、山梨酸、山梨酸鉀、飽和蔬菜脂肪酸之部份甘油酯混合物、水、鹽,或電解質,諸如,硫酸魚精蛋白、磷酸二鈉氫、磷酸鉀氫、氯化鈉、鋅鹽、膠體矽石、三矽酸鎂、聚乙烯吡咯吡咯烷酮、以纖維素為主之物質、聚乙二醇、羧甲基纖維素鈉、聚丙烯酸酯、蠟、聚乙烯-聚氧丙烯-嵌段共聚物、聚乙二醇,及羊毛脂。
本發明之藥學組成物可以口服、腸胃外、藉由吸入噴灑、經直腸、經鼻、經臉頰、經陰道、或經由一植入式貯存器投藥。口服投藥係較佳。本發明之藥學組成物可含有任何傳統之非毒性藥學上可接受之載劑、佐劑,或載體。術語腸胃外於此處使用時包含皮下、皮內、靜脈內、肌內、動脈內、滑膜內、胸骨內、鞘內、損害內及顱內之注或灌注技術。
藥學組成物可呈一無菌可注製備物型式,例如,為一無菌可注之水性或油質懸浮液。此懸浮液可依據此項技藝已知之技術,使用適合分散或濕化劑(諸如,Tween 80)及懸浮劑調配。無菌可注製備物亦可為於一無毒性腸胃外可接之稀釋劑或溶劑內之一無菌可注溶液或懸浮液,例
如,於1,3-丁二醇人之溶液。可被使用之可接受載體及溶劑係甘露醇、水、林各氏液,及等滲氯化鈉溶液。此外,無菌不揮發性油傳統作為一溶劑或懸浮介質。為了此目的,任何品牌之不揮發性油可被使用,包含合成之單或二甘油酯。諸如油酸之脂肪酸及其甘油酯衍生物可用於製備可注物,如諸如橄欖油或蓖麻油之天然藥學上可接受之油般,特別是其等之聚氧乙基化型式。此等油溶液或懸浮液亦可含有一長鏈稀釋劑或分散劑,諸如,於Ph.Helv中所述者,或相似之醇。
本發明之藥學組成物亦可以任何口服可接受藥劑型式口服投藥,不受限制地包括膠囊、錠劑、粉末、顆粒,及水性懸浮液及溶劑。此等藥劑型式係依據熟習藥學配製技藝者所知技術製備。於口服使用之情況,普遍使用之載劑包含乳糖及玉米澱粉。諸如硬脂酸鎂之潤滑劑亦可典型上被添加。對於膠囊型式之口服投藥,有用之稀釋劑包含乳糖及經乾燥之玉米澱粉。當水性懸浮液以口服投藥,活性成份可與乳化劑及懸浮劑混合。若要的話,某些甜化劑及/或調味劑及/或著色劑可被添加。
本發明之藥學組成物亦可以用於直腸投藥之栓劑型式投藥。此等組成物可藉由使本發明之一化合物與一於室溫係固體但於直腸溫度係液體且因此於直腸內會熔融釋放活性組份之適合非刺激性賦形劑混合而製備。此等材料不受限制地包括可可脂、蜂蠟,及聚乙二醇。
本發明之藥學組成物可藉由鼻用氣溶膠或吸入
而投藥。此等組成物係依據藥學調配技藝已知之技術製備,且可以於食鹽水內之溶液,使用苯甲醇或其它適合防腐劑、增強生物可用率之吸收促進劑、氟碳化物,及/或此項技藝已知之其它助溶或分散劑而製備。
本發明之化合物可以每一劑量約1至約20,000μg/kg之劑量投藥,例如,每一劑量約1至約10,000μg/kg,約1至約5,000μg/kg,約1至約3,000μg/kg,約1至約2,000μg/kg,約1至約1,500μg/kg,約1至約1,000μg/kg,約1至約500μg/kg,約1至約250μg/kg,約1至約100μg/kg,約1至約50μg/kg,或約1至約25μg/kg,其係依欲被治療或預防之病況,及以此化合物投藥之對象之特徵而定。於許多例子,劑量可為每一劑量約1至約10μg/kg。於一特別實施例,劑量可為每一劑量約250μg/kg,每一劑量約100μg/kg,約50μg/kg或約10μg/kg。對於一特定化合物之給藥方案可由可獲得此揭露內容之熟習此項技藝者輕易決定。
於一特別實施例,本發明之藥學組成物另外包含一或多種另外之活性藥學成份。本發明之化合物可與一或多種另外之活性藥學成份投藥,諸如,大麻素、油醯基乙醇醯胺,或棕櫚醯基乙醇醯胺。此可呈包含本發明化合物及一或多種另外之活性藥學成份之單一組成物之型式。另外,此可呈二或更多之分開組成物,其中,本發明化合物可包含於一組成物內,且一或多種另外之活性藥學成份係包含於一或多種分開組成物內。
本發明化合物之投藥因此可與此一或多種另外
之活性藥學成份同時,或錯開。
於第三方面,本發明提供一種依據本發明第一方面之化合物,或一種依據第二方面之組成物用於治療。
於第四方面,本發明提供一種依據本發明第一方面之化合物,或一種依據第二方面之組成物用於治療或預防其發展或症狀係與FAAH酵素之基質有關之病況。
本發明亦提供一種依據本發明第一方面之化合物,或一種依據第二方面之組成物於製造用於治療或預防其發展或症狀係與FAAH酵素之基質有關之病況的藥物之用途。
其發展或症狀係與FAAH酵素之基質有關之數種病況係熟習此項技藝者已知。此等之一些係如上所探討。
於第五方面,本發明亦提供一種治療或預防其發展或症狀係與FAAH酵素之基質有關之病況的方法,此方法包含對需要此治療或預防之一對象投用一治療有效量之一依據本發明第一方面之化合物,或一依據第二方面之組成物。
一依據第四方面之化合物,或一依據第五方面之方法,其中,病況係一與內源性大麻素系統有關係之異常。
於某些實施例,欲被治療之病況可選自:(i)疼痛,特別是急性或慢性神經病性疼痛,諸如,偏頭痛及神經病變疼痛(例如,糖尿病神經病變疼痛、帶狀皰疹後神經痛、三叉神經痛);偏頭痛;急性或慢性發炎性疼痛,諸如,與發炎性疾病有關者,諸如,關節炎、
類風濕性關節炎、骨關節炎、骨質疏鬆症、脊椎炎、痛風、血管炎、克隆氏症,及大腸激躁症;急性或慢性週邊疼痛;癌症疼痛;(ii)頭暈、嘔吐,及噁心,特別是化療造成;(iii)飲食異常,特別是食慾異常、代謝異常、厭食症,及各種自然之惡病質;(iv)神經及精神病理學,諸如,顫抖、異動症、肌張力不全、噁心、嘔吐、成癮疾病(諸如,對藥物或酒精成癮)、痙攣、強迫行為、妥瑞氏症候群、所有型式之任何自然及原始之憂鬱及焦慮、失眠、情緒異常,及精神病,諸如,精神分裂;(v)急性及慢性神經退化性疾病,諸如,巴金森氏症、阿茲罕默氏症、老年癡呆症、享丁頓舞蹈症、與腦缺血及顱與骨髓創傷有關之病變;(vi)癲癇;(vii)睡眠異常,包含睡眠窒息;(viii)心血管疾病,諸如,心臟衰竭、高血壓、循環性休克、心肌再灌注損傷、心律不整、動脈硬化/動脈粥狀硬化、心臟病、心臟缺血、血管炎,及腎缺血;(ix)癌症,例如,良性皮膚腫瘤、腦部腫瘤及乳頭狀瘤、前列腺腫瘤,及顱內腫瘤(膠質母細胞瘤、髓上皮瘤、髓母細胞瘤、神經母細胞瘤、胚胎組織起源腫瘤、星狀細胞瘤、星狀母細胞瘤、室管膜瘤、寡樹突膠質瘤、脈絡叢腫瘤、神經上皮瘤、骨骺腫瘤、成室管膜細胞瘤、惡
性腦膜瘤、肉瘤病、惡性黑色素瘤,及神經鞘瘤);(x)免疫系統異常,特別是自體免疫疾病,諸如,牛皮癬、紅斑性狼瘡、結締組織疾病或膠原病.薛格連氏(Sjögren)症候群、僵直性脊椎炎、未分化脊椎炎、貝西氏病、自體免疫性溶血性貧血、多發性硬化症、肌萎縮性側索硬化症、澱粉樣變性病、移植排斥、影響漿細胞株之疾病、過敏疾病、立即或延遲性過敏症、過敏性鼻炎,或結膜炎、接觸性皮膚炎;(xi)寄生蟲、病毒或細菌感染疾病,諸如,AIDS,及腦膜炎;(xii)發炎性疾病,特別是,關節疾病,諸如,關節炎、類風濕性關節炎、骨關節炎、脊椎炎、痛風、血管炎、克隆氏症、急躁/發炎性腸道症候群、氣喘;(xiii)骨質疏鬆症;(xiv)眼部病況,諸如,高眼壓症、視網膜病變,及青光眼;(xv)肺部病況,包含呼吸道疾病、支氣管痙攣、咳嗽、氣喘、慢性支氣管炎、慢性呼吸道阻塞,及肺氣腫;(xvi)胃腸疾病,諸如,急躁/發炎性腸道症候群、發炎性腸異常、潰瘍、腸瀉、尿失禁,及膀胱發炎;(xvii)急性及慢性肝病,諸如,肝炎及肝硬化;(xviii)神經異常,諸如,神經創傷、中風、多發性硬化症、脊髓損傷、巴金森氏症、左多巴誘發異動症、享丁頓舞蹈症/舞蹈病、妥瑞症、遲發性運動不能、肌張力
不全症、肌萎縮性脊髓側索硬化症、阿茲罕默氏症,及癲癇。
於本發明之第六方面,提供一種合成N-甲基環戊胺之酸鹽的方法,此方法包含環戊胺與氯甲酸酯或碳酸二第三丁酯(di-tert-butyl carbonate)反應,形成環戊基氨基甲酸酯,其後使環戊基氨基甲酸酯還原及酸化成N-甲基環戊胺之酸鹽。
第六方面之方法可被用以有效率地製造N-甲基環戊胺之酸鹽,於製備具化學式A之化合物之一關鍵中間物。本方法提供高生產率及良好品質之產物。一較佳酸鹽係HCl鹽。但是,其它無機及有機酸鹽亦可行。
於實施例中,環戊基氨基甲酸酯之形成係於酸性條件,例如,無機鹼,諸如,NaOH(例如,3M)、NaHCO3、Na2CO3或K2CO3,或有機鹼,諸如,三乙胺、二異丙基乙胺,於有機溶劑中,諸如,THF、甲基THF、二烷、甲基第三丁醚,或二氯甲烷進行。用於此步驟之氯甲酸酯可為,例如,C1-4,諸如,乙基,氯甲酸酯。還原步驟可於諸如THF或甲基THF之有機溶劑中,使用氫化鋁(LAH)進行。溫度範圍係從30℃至迴流,較佳係於60℃。為了隔離產物,方便地係添加諸如HCl、HBr、HI(例如,濃縮)之無機酸或諸如乙酸之有機酸,以便形成N-甲基環戊胺之相對應酸鹽。
於第七方面,本發明亦提供一種用於合成N-甲基環戊胺之酸鹽的方法,此方法包含於甲胺之酸鹽存在中,使環戊酮還原胺化。
於第七方面之實施例中,還原係於一催化量之支撐於碳上之貴金屬,諸如,Pd/C(例如,5%或10%)存在中,例如,於有機鹼(諸如,三乙胺或二異丙基乙胺),及醇型溶劑(諸如,甲醇、乙醇、丙醇,或丁醇)存在中,於氫氣下發生。壓力可從大氣壓至10巴變化。可使用約50-80(或60-70)℃之溫度。第七方面之一較佳酸鹽係HCl鹽,其中,甲胺HCl被用於此方法。但是,其它無機及有機酸鹽亦可行。因此,諸如HBr、HI之無機酸鹽,或諸如乙酸之有機酸鹽可藉由類似方法製備。
依據第六或第七方面製造之N-甲基環戊胺鹽(諸如,HCl鹽)其後可用於使用此處所述之用於製備此化合物之任何方法製備具化學式A之化合物。本發明因此亦提供一種用於製備具化學式A之化合物的方法,其中,依據第六或第七方面之方法被包含。亦提供一種具化學式A之化合物,其係藉由此一方法獲得或可藉此獲得。
本發明現將藉由範例更詳細地說明。
用於合成本發明化合物之方法係於下藉由一般流程例示。所有化合物及中間物係藉由核磁共振(NMR)描述特徵。用於製備此等化合物之起始材料及試劑係可得自
商業供應商,或可藉由熟習此項技藝者顯而易知之方法製備。此等一般流程僅係例示可合成本發明化合物之方法,且此等流程之各種不同修改可被進行,且可建議給參考本揭露內容之熟習此項技藝者。
下列流程中之室溫意指範圍從20℃至25℃之溫度。
於THF(200毫升)內之苯基三甲基三溴化銨(50.1克,133毫莫耳)之溶液以滴液方式添加至於室溫之THF(200毫升)內的1-(3-硝基苯基)乙酮(20克,121毫莫耳)之攪拌溶液。反應混合物於室溫攪拌1小時。白色懸浮液被過濾,且濾餅以THF清洗,濾液於真空中蒸發,產生黃色油。然後,
殘質溶於EtOAc,且以水清洗。有機層被乾燥(MgSO4),且於真空中蒸發產生黃色油,其被固化成黃色固體。固體自丙-2-醇再結晶,且最終產物被隔離,呈灰白色固體。2-溴-1-(3-硝基苯基)乙酮(20.5克,70%產率)。
(1H,600MHz,20℃,CDCl3)δ:8.83(1H,t,J=2Hz),8.49(1H,ddd,J=1.0,2.3,8.2Hz),8.34(1H,ddd,J=1.0,1.7,7.8Hz),7.75(1H,t,J=8.1Hz),4.49(2H,s)。
(13C,150MHz,20℃,CDCl3)δ.:189.3,148.5,135.1,134.4,130.2,128.1,123.8,29.9
熔點(mp):90-91℃。
溴化反應之另一路徑係如下:對於乙酸(10vol)內之3-硝基苯乙酮(1wt,1eq)之溶液,於不少於2小時期間,溫度維持低於30℃,注入溴溶液(0.34vol,1,08eq)。於25℃與30℃間之溫度攪拌1小時後,對此反應檢測完全度。反應完全後,注入冷水(12vol),形成白色沉澱。懸浮液於15℃另外攪拌1小時,然後過濾。濾餅以水(4.5vol)清洗。產物於不多於45℃之溫度於真空下乾燥至乾燥損失<1.0%為止。溴化產物之隔離產率約66%。此另外方式較佳係適於擴大。
水(8毫升)添加至2-溴-1-(3-硝基苯基)乙酮(57.1
克,234毫莫耳)及甲醯胺(116毫升,2.9莫耳)之攪拌懸浮液。混合物於140℃攪拌5小時。棕色殘質倒至300毫升水中,且形成之沉澱物藉由過濾分離,且以1M HCl溶液清洗。濾液以50% NaOH鹼化,且形成之黃色沉澱物藉由過濾分離,且以水清洗。固體被乾燥,然後,自丙-2-醇再結晶。4-(3-硝基苯基)-1H-咪唑(7.05克,44%產率)。
(1H,600MHz,20℃,DMSO)δ.:12.37(1H,s,br),8.58(1H,mt,J=2.0Hz),8.21(1H,ddd,J=1.0,1.6,7.8Hz),8.02(1H,ddd,J=1.0,2.5,8.2Hz),7.88(1H,dd,J=1.2Hz),7.79(1H,dd,J=1.1Hz),7.64(1H,t,J=8.1Hz)
(13C,150MHz,20℃,DMSO)δ:148.4,137.9,136.8,136.6,130.5,130.0,120.5,118.3,114.6
熔點:221℃(dec.)
以此方面之此步驟的增強性而言,發現當溫度從140增加至170℃,單獨使用甲醯胺(即,無水)作為懸浮介質導致增加產率(最高達80%)。因此,一增強之方案如下:於甲醯胺(10vol)中之2-溴-1-(3-硝基苯基)乙酮(1wt,1eq)之溶液加熱至170℃,且於不多於4小時期間攪拌。攪拌4小時後,檢查反應完全度。反應完全後,混合物冷卻至室溫,且注入水(15vol)。懸浮液被過濾,且濾餅以3N HCl(2vol)清洗,且母液被再次過濾。藉由添加50% NaOH(2vol)使溶液pH調整至14,使混合物溫度維持於0℃與5℃之間。使懸浮液於0/5℃攪拌NLT30分鐘後,過濾及以水(5vol)清洗濾餅。產物於真空下於不多於45℃之溫度乾
燥至乾燥損失<1.0%為止。
於THF(126毫升)內之N-甲基環戊胺(10克,101毫莫耳)之溶液以滴液方式添加至於0℃之光氣溶液(63.7毫升,121毫莫耳,20%,於甲苯內),產生白色懸浮液。反應混合物於室溫攪拌1小時。溶液倒至冰內。有機層以EtOAc稀釋,以1M HCl個別清洗,乾燥(MgSO4),及於真空蒸發產生澄清之移動油。環戊基(甲基)胺甲醯氯(13.1克,80%產率)。
(1H,600MHz,20℃,CDCl3)δ.:4.65(1H,m),3.0,2.93(3H,2個單重態),1.92(2H,m),1.73(2H,m),1.59(4H,m)
(13C,150MHz,20℃,CDCl3)δ.:149.7,149.3,61.1,59.5,33.1,31.1,28.8,28.5,24.0
胺甲醯化步驟亦可如下般使用三光氣/DCM及碳酸鈉進行:於DCM(10vol)內之三光氣(1.2wt,0.4eq)之溶液冷卻至0/5℃,且於不多於10分鐘期間攪拌。於DCM(5vol)內之N-甲基環戊胺(1wt,1eq)之溶液被注入,反應溫度維持低於10℃。胺溶液添加後,注入Na2CO3(2.14wt,2eq),且加溫至室溫。攪拌2小時後,反應混合物被過濾,且濾餅以DCM(1vol)清洗。濃縮至乾燥後,獲得黃色油,且係以未進
一步處理下使用。
氫化鈉(5.1克,127毫莫耳,於礦物油內之60%分散液)一部份一部份地添加至於0℃之於THF(500毫升)內之4-(3-硝基苯基)-1H-咪唑(20克,106毫莫耳)的攪拌懸浮液。黃色懸浮液變成暗紅色懸浮液。混合物於室溫攪拌30分鐘,其後添加於THF(26毫升)內之環戊基(甲基)胺甲醯氯(25.6克,159毫莫耳)之溶液。然後,懸浮液於室溫攪拌2小時。水於0℃添加,且THF被蒸發。有機殘質以DCM萃取,有機層被分離,乾燥(MgSO4),及於真空中蒸發產生米黃色固體。固體以丙-2-醇磨碎。N-環戊基-N-甲基-4-(3-硝基苯基)-1H-咪唑-1-羧醯胺(25.18克,76%產率)。
(1H,600MHz,20℃,CDCl3)δ.:8.63(1H,mt,J=2.0Hz),8.16(1H,ddd,J=1.0,1.6,7.8Hz),8.14(1H,ddd,J=1.0,2.3,8.2Hz),7.96(1H,d,J=1.3Hz),7.65(1H,dd,J=1.3Hz),7.58(1H,t,J=8.1Hz),4.45(1H,m),3.03(3H,s),1.98(2H,m),1.80(2H,m),1.73(2H,m),1.66(2H,m)
(13C,150MHz,20℃,CDCl3)δ.:151.3,148.7,140.1,137.3,134.9,130.9,129.7,122.1,119.9,114.6,59.4,
31.3,28.9,24.4
熔點:121-122℃
乙酸乙酯(160毫升)及EtOH(160毫升)之混合物於氬氣氛圍下添加至濕的Pd/C(0.846克,0.795毫莫耳,10%)。對此一部份一部份地添加N-環戊基-N-甲基-4-(3-硝基苯基)-1H-咪唑-1-羧醯胺(5克,15.91毫莫耳),且懸浮液於氫氣氛圍下於室溫攪拌隔夜。混合物以氬氣沖洗,且經由塞里塑料(celite)過濾,且塞里塑料以DCM清洗。濾液於真空中蒸發,產生澄清油,其被固化成無色固體。固體自丙-2-醇再結晶。4-(3-胺基苯基)-N-環戊基-N-甲基-1H-咪唑-1-羧醯胺(3.62克,80%產率)。
(1H,600MHz,20℃,DMSO)δ.:8.06(1H,d,J=1.3Hz),7.77(1H,d,J=1.1Hz),7.08(1H,t,J=1.9Hz),7.0(1H,t,J=7.8Hz),6.98(1H,md,J=7.7Hz),6.45(1H,ddd,J=1.2,2.3,7.7Hz),5.07(2H,s),4.37(1H,m),2.92(3H,s),1.87(2H,m),1.68(4H,m),1.53(2H,m)
(13C,150MHz,20℃,DMSO)δ.:151.2,148.8,141.4,137.3,133.8,129.0,113.7,112.9,112.8,110.4,58.4,
31.2,28.2,24.0
熔點:108-109℃
於另一實施例,此步驟之苯胺衍生產物可於未純化下用於其後步驟,即,使得此及其後步驟可被縮短。
氰酸鉀(0.445克,5.49毫莫耳)以一部份一部份地添加至於0℃之水(4毫升)內之2N氯化氫(2.286毫升,4.57毫莫耳)之混合物中之4-(3-胺基苯基)-N-環戊基-N-甲基-1H-咪唑-1-羧醯胺(1.3克,4.57毫莫耳)之攪拌溶液。混合物於室溫攪拌24小時。添加氰酸鉀(0.220克,2.74毫莫耳),且混合物於室溫攪拌另一夜。添加水,且有機層以7:3之DCM/丙-2-醇的混合物稀釋。有機層被分離,且以1N HCl水溶液清洗。有機層被分離,乾燥(MgSO4),及於真空中蒸發,產生無色發泡體。產物藉由管柱色層分析術(矽石,DCM/MeOH 5%,10%)純化,且被隔離,呈無色固體。固體自0℃之EtOH再結晶。N-環戊基-N-甲基-4-(3-脲基苯基)-1H-咪唑-1-羧醯胺(0.403克,26%產率)。
上述本發明化合物係藉由熔點及如下詳述之
NMR描述特徵。NMR光譜係於一Bruker 600MHz Avance III光譜儀上以溶液作為內部標準物而記錄。13C光譜係於150MHz記錄,且1H光譜係於600MHz記錄。數據係以下列順序報導:近似化學位移(ppm),質子數,多重性(br,寬;d,雙重態;m,多重態;s,單重態,t;三重態),及偶合常數(Hz)。
化合物編號1(熔點:204℃)
(13C,150MHz,20℃,DMSO)δ.:156,151.1,140.9,140.8,137.5,133.7,128.9,117.9,116.6,114.2,114.2,58.4,31.2,28.2,24。
(1H,600MHz,20℃,DMSO)δ.:8.55(1H,s),8.09(1H,d,J=1.2Hz),7.86(1H,d,J=1.2Hz),7.85(1H,t,J=1.8Hz),7.35(1H,md),7.34(1H,md),7.22(1H,t,J=7.8Hz),5.84(2H,s),4.36(1H,m),2.93(3H,s),1.87(2H,m),1.69(4H,m),1.54(2H,m)。
此最後步驟之增強(苯基環上之尿素形成)係由使用乙酸替代水作為4-(3-胺基苯基)-N-環戊基-N-甲基-1H-咪唑-1-羧醯胺之溶劑所組成。此導致改良產率(約78%),及改良之隔離方案。此增強步驟可描述如下:4-(3-胺基苯基)-N-環戊基-N-甲基-1H-咪唑-1-羧醯胺溶於室溫之AcOH(8.8vol)。對於室溫之形成溶液,添加於水(0.9vol)中之氰酸鉀(0.65wt,2.5eq)之溶液。形成之溶液於室溫攪拌至反應完全為止(起始材料<0.1%)。於1小時內,發生尿素產物沉澱。對形成之漿料添加水(5vol),且更多固體出現。然
後,米黃色懸浮液於室溫老化1小時,及過濾。米黃色固體以水(10vol)清洗,於真空爐乾燥下至乾燥損失<1.5%為止。
若此增強步驟(使用乙酸)導致N-乙醯化苯胺雜質,可實施再結晶。此可為如下:對於室溫之於乙酸(5vol)中之尿素產物(1wt)的溶液,於30分鐘期間以滴液方式添加水(5vol)。於加晶種後,添加水(2vol),且漿料於室溫老化1小時。漿料冷卻至10℃,於10℃攪拌至少1小時,及過濾。灰白色固體以水/乙酸之9:1混合物(2vol),水(10vol)清洗,於55℃之真空爐內乾燥。然後,灰白色固體(0.82wt)在室溫溶於乙酸(3.96vol),且水(4.1vol)於30分鐘期間以滴液方式添加。然後,對此溶液,添加晶種,其後添加水(1.6vol)。形成之漿料於室溫攪拌至少1小時,然後,冷卻至10℃。使漿料於10℃老化至少1小時,過濾固體,以水/乙酸之9:1混合物(1.6vol),水(10vol)清洗,於55℃之真空爐內乾燥至乾燥損失係<1.5%為止。
活體內試驗係依據下述方案實施。BRh(腦勻漿)指示於中樞神經組織之抑制,於此情況,腦部,且LVh(肝勻漿)指示於週邊組織之抑制,於此情況,肝臟。對照組係反應混合物扣掉試驗化合物。因此,試驗化合物之低數值指示強抑制劑.。100之數值指示無可測得之抑制發生。
用於實驗之動物係自Interfauna Ibérica(西班牙)獲得之公NMRI小鼠(重27-44克)。小鼠係每一籠保持5隻,於控制之環狀條件下(12小時之光/暗循環及於室溫22±1℃)。食物及自來水係自由採食,且實驗皆於白天時間進行。
動物係使用動物餵食不銹鋼彎曲針(Perfectum,U.S.A.),經由口服路徑投用30mg/kg或3mg/kg之本發明化合物或比較物化合物(8ml/kg;懸浮於0.5%羧甲基纖維素(CMC)或於水中助溶之化合物)或載體(對照組)。犧牲前15分鐘,動物係以戊巴比妥60mg/kg,經腹膜內投藥而麻醉。肝臟、左肺葉及無小腦之腦部的片斷被移除,且置於含有膜緩衝劑(3mM MgCl2,1mM EDTA,50mM Tris HCl pH 7.4)之塑膠藥瓶內。組織貯存於-30℃至分析為止。
動物係於投用化合物前被禁食隔夜,>18小時之時間點除外,此時食物係於投藥日上午移除且化合物係於同日下午投藥。然後,動物僅被供水,而無其它東西。
所有動物程序係嚴格按照歐洲保護用於實驗及其它科學目的之脊椎動物之法規(European Directive for Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes)(86/609CEE)及葡萄牙立法(Portuguese legislation)(Decreto-Lei 129/92,Portarias 1005/92 e 1131/97)進行。使用之動物數量符合現今規定及科學誠信之可能最小數量。
大麻素[乙醇胺-1-3H-](40-60Ci/毫莫耳)係自American Radiochemicals獲得。所有其它試劑係自Sigma-Aldrich獲得。Optiphase Supermix係自Perkin Elmer獲得,且活性炭係自Sigma-Aldrich獲得。
組織於冰上解凍且於10體積量之膜緩衝劑(3mM MgCl2,1mM EDTA,50mM Tris HCl pH 7.4)內以Potter-Elvejhem(腦-8個衝程,500rpm)或Heidolph Diax(肝臟-2衝程,於位置5,20秒,30秒暫停)均質化。
組織內之總蛋白質係以BioRad蛋白質分析(BioRad)使用BSA標準曲線測定(50-250μg/ml)。
反應混合物(200μl之總體積)含有:2μM AEA(2μM AEA+5nM 3H-AEA),0.1%無脂肪酸之BSA,15μg(腦),5μg(肝臟)或50μg(肺)蛋白質,其係於1mM EDTA,10mM Tris內,pH 7.6。於37℃之15分鐘預培養期後,反應係藉由添加基質溶液(冷的AEA+經放射性標記之AEA+BSA)而開始。反應進行10分鐘(腦及肺)或7分鐘(肝臟),其後藉由添加400μl之活性炭懸浮液(8克活性炭,於32毫升0.5M HCl,連續攪拌)而中止。於室溫30分鐘培養期並且攪拌後,活性炭藉由於microfuge離心處理(10分鐘,13000rpm)而沉降。200μl之上清液添加至事先分配於24-孔板之800μl Optiphase Supermix閃爍雞尾酒液。每分鐘之計數(cpm)係以一MicrobetaTriLux閃爍計數器測定。
於每一分析,空白組(無蛋白質)被製備。
剩餘酶活性百分率係相對於對照組且於減去空白組後算得。
測試化合物係以增加劑量(10、3、1、0.3、0.03及0.01mg/kg)提供給動物,且於投藥後8小時,FAAH活性係依據前述活體內方案判定,然後,ED50值係藉由“Prisma”軟體,以95%之信賴區間計算。
測試化合物之安定性係於NADPH存在中或缺乏中,於MLM(小鼠肝微粒體)或HLM(人類肝微粒體)實施。
安定性係使用含有1毫克/毫升之總蛋白質、MgCl2 5mM,及50mM K-磷酸鹽緩衝劑之培養混合物(100μl總體積)測量。樣品係於NADPH 1mM存在中或缺乏中培養。反應預培養5分鐘,反應以試驗下之化合物起始(對於HLM係5μM,且對於MLM係50μM)。樣品於37℃之搖動水浴中培養60分鐘。反應藉由添加100μl之乙腈而停止。然後,樣品被離心處理,過濾,且上清液注於HLPC-MSD內。測試化合物溶於DMSO,且反應內DMSO最終濃度係低於0.5%(v/v)。於T0,添加乙腈,其後添加化合物。所有實驗係以樣品實施兩次。
化合物1(N-環戊基-N-甲基-4-(3-脲基苯基)-1H-咪唑-1-羧醯胺;亦稱為具化學式A之化合物,如上)被測試。再者,揭露於WO 2010/074588之比較物化合物被測試。此
等係如下:比較物化合物1-N-環己基-4-(3-胍其苯基)-N-甲基-1H-咪唑-1-羧醯胺。
比較物化合物2-N-環戊基-4-(4-氟-3-羥基苯基)-N-甲基-1H-咪唑-1-羧醯胺。
比較物化合物係實質上相似於化合物1,即使此等化合物間具有明確差異。比較物化合物2亦實質上相似於化合物1,但再次地,於此二化合物間具有明確差異。
由上表可看出,以於肝臟中之FAAH抑制而言,化合物1係最有效之化合物。特別地,化合物1係遠比比較物化合物1更有效。
週邊選擇性係藉由使肝臟內之FAAH活性除以腦內之FAAH活性而計算。如此作時,較低數值顯示化合物係更具週邊選擇性。結果係於下表中提供。
此等結果顯示化合物1係以多於2之因數係最具
週邊選擇性之化合物。再者,化合物1係遠比比較物化合物1更具週邊選擇性。
化合物1及比較物化合物2之於不同濃度之與FAAH活性有關之另外數據係於下表中提供。
可看出,於所有劑量,與比較物化合物2相比,投用化合物1後,FAAH活性遠為較低。特別地,於0.1毫克/公斤,於服藥後8小時,與比較物化合物2相比,對於化合物1,FAAH活性係明顯較低。此顯示化合物1係比比較物化合物2明顯更有效。於0.1毫克/公斤,化合物1係比比較物化合物2多超過10倍之效果。此於效果上係一驚人的重大差異。此數據亦係化合物1係代謝安定之證據,因為當進行活體內抑制實驗時,化合物之代謝安定性於抑制程度及抑制發生之時間長度亦扮演角色。
下表顯示於小鼠口服投藥後之化合物的FAAH抑制ED50數據(中間有效劑量,於肝臟產生50%之FAAH抑制所需之化合物劑量)。信賴區間(95%)被包括。
下表顯示化合物1及比較物化合物2之代謝安定
性。安定性數據係以1小時曝露於MLM或HLM後剩餘化合物之%而提供。100%意指無代謝反應,且0%係相對應於完全酶降解。“CYP-“係指無輔助因子(NADPH),其對於CYP代謝反應係重要。因此,“CYP-”可被視為對照值。“CYP+”指輔助因子存在,且酶降解會依據測試化合物安定性而發生。可看出,於MLM及HLM二者,化合物1係比比較物化合物2更安定。
大麻素[乙醇胺-1-3H-]係自American Radiochemicals獲得-具60Ci/毫莫耳之特別活性。所有其它試劑係自Sigma-Aldrich獲得。Optiphase Supermix係自Perkin Elmer獲得,且活性炭係自Sigma獲得。
得自4隻Wistar大鼠之冷凍腦部係於20毫升之1mM MgCl2、20mM HEPES(4-(2-羥基乙基)-1-哌乙烷磺酸)pH 7.0內以Potter-Elvejhem(8衝程,500rpm)均質化。勻漿以36000g於4℃離心處理20分鐘(Beckman,70Ti rotor)。丸
粒再次懸浮於15毫升之相同緩衝劑內,且於相同條件下離心處理。丸粒再次懸浮於15毫升之相同緩衝劑,且於37℃培養15分鐘,其後,以36000g於4℃離心處理20分鐘。然後,每一丸粒再次懸浮於10毫升之3mM MgCl2、1mM之EDTA(乙二胺四乙酸)、50mM之三(2-胺基-2-羥基甲基-丙-1,3-二醇)pH 7.4,且蛋白質係以BioRad蛋白質分析(BioRad)使用BSA(牛血清白蛋白)標準曲線判定(50-250μg/ml)。
膜懸浮液被等分且貯存於-30℃。
反應混合物(總體積200μl)含有:2μM AEA(2μM AEA+5nM 3H-AEA),0.1%無脂肪酸之BSA,5或10μg蛋白質,於1mM EDTA內,10mM TrispH 7.6,及各種濃度之化合物1。原料溶液(10mM)係於100% DMSO(二甲基亞碸)內製備,且此分析之DMSO濃度會係0.1%。於37℃時15分鐘預培養期後,反應藉由添加基質溶液(冷的AEA+經放射性標記之AEA+BSA)開始。反應進行10分鐘,其後藉由添加400μl活性炭懸浮液(8克活性炭,於32毫升0.5M HCl內,連續攪拌)而終結。於室溫30分鐘培養期並攪拌後,炭藉由於microfuge離心處理而沉降(10分鐘,15000g)。200μl之上清液添加至事先分配於24-孔板之800μl的Optiphase Supermix閃爍雞尾酒液。每分鐘之計數(CPM)或每分鐘之分解量(DPM)係於一MicrobetaTriLux閃爍計數器判定。於每一分析,空白組(無蛋白質)及對照組(無化合物)存在。
Wallac 1450 MicrobetaTriLux閃爍計量器。
計數條件係如下:
Spectramax Plus-SOFTmax® PRO軟體,3.0版
原始數據獲得係以軟體“Microbeta TriLux Windows workstation,4.01版”實施。
數據分析係使用Prism 5 for Windows軟體,5.02版(GraphPad Software Inc.,San Diego,CA)實施。化合物1
之IC50值係藉由使實驗數據與log(抑制劑)對正規化反應-變化斜率方程式擬合而判定:
使用此方案,化合物1被判定具有27nM之IC50。
由上之所有結果可看出,化合物1係比比較物化合物1及2之任一者明顯更有效,更具週邊選擇性,及/或更為代謝安定。
對於0℃之於THF(20毫升)內之環戊胺(3毫升,30.3毫莫耳)之溶液,個別添加3M氫氧化鈉(15.15毫升,45.5毫莫耳)及氯甲酸乙酯(3.47毫升,36.4毫莫耳)。形成之二相混合物於室溫攪拌4小時。反應混合物以MTBE(30毫升)及氫氧化銨(5毫升)稀釋。形成之混合物於室溫攪拌10分鐘,然後分離。有機層以水、0.5M HCl清洗,於Na2SO4乾燥,過濾。濾液於減壓下濃縮。環戊基氨基甲酸乙酯(4.35克)
係以無色油獲得,95%產率,且於未進一步純化下用於下步驟。
此反應進行良好。產物之產率及品質高。
氨基甲酸酯還原成相對應之甲胺係普偏已知。此還原通常需要使用於迴流之於THF內之過量的氫化鋰鋁(LAH)。但是,大規模使用氧化鋰鋁可能需要更複雜之流程。因此,Fieser流程被使用(對於x克之LAH,使用x毫升之水,x毫升之15至25% NaOH,然後,3x毫升之水),此係較安全且較簡單之操作。首先嚐試係使用LAH對氨基甲酸第三丁酯成功地實施,Fieser流程,其後添加濃HCl形成氫氯酸鹽。N-甲基環戊胺氫氯酸鹽於隔離後係以63%獲得。自此第一嚐試形成之品質及產率導致使用氨基甲酸乙酯重複,此導致83%之莫耳產率,且品質範圍:>98%,以NMR。
於室溫於氮氣下,對於THF(20毫升)內之LAH(2,414克,63,6毫莫耳,5eq)之懸浮液,於20分鐘期間添加於THF(8毫升)內之環戊基氨基甲酸乙酯(2克,12,72毫莫耳)。注意:氣體釋出。滴液漏斗以THF(2毫升)沖洗。反應混合物於6小時期間加熱至65℃(內部溫度,迴流)。懸浮液冷卻至0℃(水-冰浴)。懸浮液以MTBE(30毫升)稀釋。對此懸浮液,以滴液方式添加2.4毫升之水(觀察到強烈氣體釋出及放熱),滴入3.6毫升之10% NaOH(需充份攪拌),且最後滴入7.2毫升的水。形成之漿料加溫至室溫,且於室溫攪拌30分鐘。對此白色懸浮液,添加MgSO4(10克)。形成之
漿料攪拌10分鐘,然後過濾。固體以MTBE(20毫升)清洗。
對混合之濾液,添加濃HCl(1,272毫升,15,27毫莫耳,1.2eq)。形成之混合物於室溫攪拌隔夜,然後,濃縮至乾燥。殘質溶於丙-2-醇(20毫升),然後,濃縮至2vol(4毫升)。然後,對形成之溶液,添加MTBE(12毫升)。白色結晶固體出現。漿料於室溫攪拌1小時,然後,固體被收集,以MTBE(4毫升)清洗,於50℃之真空爐乾燥4小時。獲得第一批白色針狀物(884毫克),混合之母液及清洗液濃縮至乾燥。乙酸異丙酯(iPrOAc)添加至殘質,白色結晶開始出現。添加更多iPrOAc,但一些固體於燒瓶壁上出現。添加一些DCM,且獲得澄清固體。DCM被移除,且白色固體出現,被過濾及以iPrOAc清洗。白色結晶固體於50℃之真空爐內乾燥4小時。獲得第二批白色針狀物(547毫克)。N-甲基環戊胺氫氯酸鹽係以白色針狀物獲得,83%莫耳產率。
於一催化量之三乙胺及Pd/C存在中,於氫氣壓下,於甲醇中,於65℃使用環戊酮及N-甲胺氫氯酸鹽被發現產生最佳結果。於此等條件下,N-甲基環戊胺氫氯酸鹽係以白色固體隔離,49%產率。
鈀來源及試劑當量被測試以改良產物之產率及品質(移除甲胺氫氯酸鹽)。使用Pd/C(JM,5R39糊料)及些微過量之甲胺氫氯酸鹽(1.1eq),可使產率改良最高達69%。
注意甲胺氫氯酸鹽之移除可藉由於碳酸鈉存在中,使N-甲基環戊胺氫氯酸鹽懸浮於二氯甲烷,其後蒸餾而進行。最終產物中未檢測出甲胺。
對於碳上之鈀5%,5R 39糊料(0.75克,0.176毫莫耳,0.001eq),連續地添加MeOH(105毫升),甲胺氫氯酸鹽(13.24克,196毫莫耳),環戊酮(15,77毫升,178毫莫耳),及最後之三乙胺(0.621毫升,4.46毫莫耳)。形成之漿料置於一高壓釜內,且注入5巴之氫氣。高壓釜於65℃加熱及攪拌隔夜。反應混合物緩慢冷卻,且TLC(洗提液PE/乙酸乙酯8:2,浸液高錳酸鹽)顯示無起始材料。黑色漿料經由塞里塑料過濾,且以MeOH(10毫升)清洗。甲醇被移除,且以異丙醇(60毫升)替代。溶液濃縮至2vol,且添加異丙基醚(60毫升)。形成之混合物於室溫攪拌。觀察到白色固體,然後,漿料於0℃攪拌1小時,然後過濾。固體以異丙醚/丙-2-醇9:1(30毫升)清洗,於真空爐內乾燥隔夜。獲得N-甲基環戊胺HCl之白色結晶固體(16.9克,69.5%產率)。
Claims (11)
- 一種具有下列結構的化合物:
- 一種藥學組成物,其包含如請求項1之化合物與一或多種藥學上可接受的賦形劑。
- 如請求項2之藥學組成物,其進一步包含一或多種額外的活性藥學成份,諸如大麻素、油醯基乙醇醯胺,或棕櫚醯基乙醇醯胺。
- 如請求項1之化合物或如請求項2或3之組成物,係用於治療。
- 如請求項1之化合物或如請求項2或3之組成物,係用於治療或預防一發展或症狀與FAAH酵素之基質有關的病況。
- 一種治療或預防一病況之方法,該病況是與發展或症狀與FAAH酵素之基質有關,該方法包含對一需要此治療或預防之對象投予一治療有效量之如請求項1之化合物或如請求項2或3之組成物。
- 如請求項5的用途之化合物或如請求項6之方法,其中該病況係一與內源性大麻素系統(endocannabinoid system)有關的病症(disorder)。
- 如請求項7之化合物或方法,其中,該病症係選自食欲調控(appetite regulation)、肥胖、代謝異常、惡病質、厭食、疼痛、發炎、神經毒性、神經外傷、中風、多發性硬化症、脊椎損傷、巴金森氏症、左多巴誘發異動症、享丁頓舞蹈症、妥瑞症、遲發性運動不能、肌張力不全、肌萎縮性側索硬化症、阿茲罕默氏症、癲癇、精神分裂症、焦慮、憂慮、失眠、噁心、嘔吐、酒精障礙、諸如鴉片劑、尼古汀、古柯鹼、酒精及精神興奮劑之藥物成癮、高血壓、循環休克、心肌再灌注損傷、動脈粥狀硬化、氣喘、青光眼、視網膜病變、癌症、發炎性腸病、諸如肝炎及肝硬化之急性及慢性肝病、關節炎,以及骨質疏鬆症。
- 一種用於合成N-甲基環戊胺之酸鹽的方法,該方法包含使環戊胺與氯甲酸酯(chloroformate)或碳酸二第三丁酯(di-tert-butyl carbonate)反應,以形成環戊基氨基甲酸酯(cyclopentylcarbamate),其後使該環戊基氨基甲酸酯還原並酸化成N-甲基環戊胺之酸鹽。
- 一種用於合成N-甲基環戊胺之酸鹽的方法,該方法包含在甲胺之酸鹽存在下,使環戊酮還原胺化。
- 一種用於合成如請求項1之化合物的方法,其中包含如請求項9或請求項10之方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261674970P | 2012-07-24 | 2012-07-24 | |
US61/674,970 | 2012-07-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201408650A true TW201408650A (zh) | 2014-03-01 |
TWI624460B TWI624460B (zh) | 2018-05-21 |
Family
ID=48986199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102126473A TWI624460B (zh) | 2012-07-24 | 2013-07-24 | 尿素化合物及其作爲酵素抑制劑之用途 |
Country Status (33)
Country | Link |
---|---|
US (3) | US9549915B2 (zh) |
EP (1) | EP2890684B1 (zh) |
JP (1) | JP6317345B2 (zh) |
KR (1) | KR102137714B1 (zh) |
CN (1) | CN104487422B (zh) |
AR (1) | AR091888A1 (zh) |
AU (1) | AU2013293650B2 (zh) |
BR (1) | BR112015001546B1 (zh) |
CA (1) | CA2879726A1 (zh) |
CL (1) | CL2015000178A1 (zh) |
CY (1) | CY1120148T1 (zh) |
DK (1) | DK2890684T3 (zh) |
ES (1) | ES2667056T3 (zh) |
HK (1) | HK1211920A1 (zh) |
HR (1) | HRP20180543T1 (zh) |
HU (1) | HUE037085T2 (zh) |
IL (1) | IL236630B (zh) |
IN (1) | IN2015DN00688A (zh) |
LT (1) | LT2890684T (zh) |
ME (1) | ME03018B (zh) |
MX (1) | MX365772B (zh) |
NO (1) | NO2923395T3 (zh) |
NZ (1) | NZ704651A (zh) |
PH (1) | PH12015500156B1 (zh) |
PL (1) | PL2890684T3 (zh) |
PT (1) | PT2890684T (zh) |
RS (1) | RS57146B1 (zh) |
RU (1) | RU2685425C2 (zh) |
SG (1) | SG11201500498SA (zh) |
SI (1) | SI2890684T1 (zh) |
TW (1) | TWI624460B (zh) |
UA (1) | UA116542C2 (zh) |
WO (1) | WO2014017936A2 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015001546B1 (pt) * | 2012-07-24 | 2021-02-23 | Bial-Portela & Ca, S.A | compostos de ureia e sua utilização como inibidores enzimáticos |
US9047327B2 (en) | 2012-12-03 | 2015-06-02 | Google Technology Holdings LLC | Method and apparatus for developing a social hierarchy |
ES2640800T3 (es) | 2013-07-24 | 2017-11-06 | BIAL - PORTELA & Cª, S.A. | Imidazolcarboxamidas y su uso como inhibidores de la FAAH |
GB201401198D0 (en) | 2014-01-24 | 2014-03-12 | Bial Portela & Ca Sa | Process for the syntheis of substituted urea compounds |
US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
SG10201807034XA (en) | 2017-09-05 | 2019-04-29 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
EP0014810A3 (en) | 1979-01-18 | 1980-11-26 | Fbc Limited | Pesticidal pyrazoles, their production, compositions and uses, as well as intermediates and their preparation |
JPH01203366A (ja) | 1988-02-10 | 1989-08-16 | Mitsui Petrochem Ind Ltd | N−置換イミダゾール誘導体 |
JP3457669B2 (ja) | 1992-10-28 | 2003-10-20 | 富山化学工業株式会社 | 新規な1,2−ベンゾイソオキサゾール誘導体またはその塩,それらからなる脳保護剤 |
ATE255564T1 (de) * | 1994-09-26 | 2003-12-15 | Shionogi & Co | Imidazolderivat |
DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
PL1849773T3 (pl) * | 2005-02-17 | 2014-03-31 | Astellas Pharma Inc | Pochodne piperazyny do leczenia nietrzymania moczu i bólu |
FI20075264A0 (fi) * | 2007-04-18 | 2007-04-18 | Kuopion Yliopisto | Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina |
WO2009126624A1 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
WO2010074588A2 (en) * | 2008-12-24 | 2010-07-01 | BIAL - PORTELA & Cª, S.A. | Pharmaceutical compounds |
WO2012015324A1 (en) | 2010-07-29 | 2012-02-02 | Bial - Portela & Ca, S.A. | Process for the synthesis of substituted urea compounds |
FR2965262A1 (fr) * | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de nicotinamide, leur preparation et leur application en therapeutique |
BR112015001546B1 (pt) * | 2012-07-24 | 2021-02-23 | Bial-Portela & Ca, S.A | compostos de ureia e sua utilização como inibidores enzimáticos |
-
2013
- 2013-07-24 BR BR112015001546-8A patent/BR112015001546B1/pt not_active IP Right Cessation
- 2013-07-24 HU HUE13750166A patent/HUE037085T2/hu unknown
- 2013-07-24 RS RS20180433A patent/RS57146B1/sr unknown
- 2013-07-24 US US14/416,675 patent/US9549915B2/en active Active
- 2013-07-24 NZ NZ704651A patent/NZ704651A/en not_active IP Right Cessation
- 2013-07-24 LT LTEP13750166.4T patent/LT2890684T/lt unknown
- 2013-07-24 IN IN688DEN2015 patent/IN2015DN00688A/en unknown
- 2013-07-24 PL PL13750166T patent/PL2890684T3/pl unknown
- 2013-07-24 ES ES13750166.4T patent/ES2667056T3/es active Active
- 2013-07-24 SI SI201330990T patent/SI2890684T1/en unknown
- 2013-07-24 SG SG11201500498SA patent/SG11201500498SA/en unknown
- 2013-07-24 TW TW102126473A patent/TWI624460B/zh not_active IP Right Cessation
- 2013-07-24 PT PT137501664T patent/PT2890684T/pt unknown
- 2013-07-24 KR KR1020157004412A patent/KR102137714B1/ko active IP Right Grant
- 2013-07-24 UA UAA201500932A patent/UA116542C2/uk unknown
- 2013-07-24 AR ARP130102632A patent/AR091888A1/es active IP Right Grant
- 2013-07-24 EP EP13750166.4A patent/EP2890684B1/en active Active
- 2013-07-24 DK DK13750166.4T patent/DK2890684T3/en active
- 2013-07-24 AU AU2013293650A patent/AU2013293650B2/en not_active Ceased
- 2013-07-24 ME MEP-2018-100A patent/ME03018B/me unknown
- 2013-07-24 CA CA2879726A patent/CA2879726A1/en not_active Abandoned
- 2013-07-24 RU RU2015104097A patent/RU2685425C2/ru active
- 2013-07-24 CN CN201380038982.7A patent/CN104487422B/zh not_active Expired - Fee Related
- 2013-07-24 MX MX2015000968A patent/MX365772B/es active IP Right Grant
- 2013-07-24 WO PCT/PT2013/000048 patent/WO2014017936A2/en active Application Filing
- 2013-07-24 JP JP2015524220A patent/JP6317345B2/ja not_active Expired - Fee Related
- 2013-11-20 NO NO13857025A patent/NO2923395T3/no unknown
-
2015
- 2015-01-11 IL IL236630A patent/IL236630B/en active IP Right Grant
- 2015-01-23 CL CL2015000178A patent/CL2015000178A1/es unknown
- 2015-01-23 PH PH12015500156A patent/PH12015500156B1/en unknown
- 2015-12-23 HK HK15112632.2A patent/HK1211920A1/zh not_active IP Right Cessation
-
2016
- 2016-12-19 US US15/383,879 patent/US10023541B2/en active Active
-
2018
- 2018-04-04 HR HRP20180543TT patent/HRP20180543T1/hr unknown
- 2018-04-23 CY CY20181100426T patent/CY1120148T1/el unknown
- 2018-07-09 US US16/030,384 patent/US11046654B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3647051B2 (ja) | イミダゾール化合物、その製造方法及びその使用方法 | |
US11046654B2 (en) | Urea compounds and their use as enzyme inhibitors | |
WO2007017092A1 (en) | Substituted 4-benzyloxy-benzoic acid amide derivatives | |
JP2008523155A (ja) | ピリジル置換スピロ−ヒダントイン化合物およびその使用 | |
US20200255412A1 (en) | Imidazolecarboxamides and Their Use as FAAH Inhibitors | |
US5843945A (en) | AMPA antagonists and a method of treatment | |
JPH06228112A (ja) | (1h,4h)キノキサリン誘導体 | |
JP2016528227A (ja) | ウレア化合物および酵素阻害剤としてのそれらの使用 | |
EP2419431A1 (fr) | Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique | |
OM et al. | SSSeS-ļO) GGGS | |
WO2015016729A1 (en) | Urea compounds and their use as faah enzyme inhibitors | |
TW200916442A (en) | 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators | |
MXPA06009686A (en) | Imidazole compounds for the treatment of neurodegenerative disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |